Premium
New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection
Author(s) -
Ceccarelli Manuela,
Venanzi Rullo Emmanuele,
Berretta Massimiliano,
Cacopardo Bruno,
Pellicanò Giovanni Francesco,
Nunnari Giuseppe,
Guarneri Claudio
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14660
Subject(s) - medicine , psoriasis , psoriatic arthritis , dermatology , adverse effect , arthritis , disease , immunology
Psoriasis is a chronic immune‐mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life‐long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL‐23/IL‐17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.